deaths (OS)

mEC - 2nd line (L2) metastatic/advanced - esophageal cancer (mEC) mEC - 2nd line (L2)

versus Standard of Care (SoC)
camrelizumab alone vs. Standard of Care (SoC) 1 certainty unassessablestatistically conclusive-27%